Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer

Kosuke HashimotoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka city, JapanCorrespondence[email protected]

https://orcid.org/0000-0001-7627-7901

Kyoichi KairaDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka city, Japan

Hisao ImaiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka city, Japan

Ayako ShionoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka city, Japan

Hiroshi KagamuDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka city, Japan

References

Illini O, Hochmair MJ, Fabikan H, et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol. 2021;13:17588359211019675. doi:10.1177/17588359211019675.
Web of Science ®Google Scholar
Bradford D, Larkins E, Mushti SL, et al. FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res. 2021;27(8):2130–2135. doi:10.1158/1078-0432.CCR-20-3558.
PubMed Web of Science ®Google Scholar
McCoach CE, Rolfo C, Drilon A, et al. Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001. J Thorac Oncol. 2022;17(6):768–778. doi:10.1016/j.jtho.2022.02.004.
PubMed Web of Science ®Google Scholar
Ahn M-J, Yang J, Yu H, et al. Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase 1b trial. J Thorac Oncol. 2016;11(4):S115. doi:10.1016/S1556-0864(16)30246-5.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date